Brian Baranick - 23 Dec 2025 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
EVP, GM, Precision Oncology
Signature
/s/ Brian Baranick by Mark Busch, attorney-in-fact
Issuer symbol
EXAS
Transactions as of
23 Dec 2025
Net transactions value
-$8,559,321
Form type
4
Filing time
30 Dec 2025, 16:30:12 UTC
Previous filing
06 Nov 2025
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Baranick Brian EVP, GM, Precision Oncology C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON /s/ Brian Baranick by Mark Busch, attorney-in-fact 30 Dec 2025 0001941313

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Options Exercise $0 +3,955 +18% $0.000000 26,323 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $204,556 -2,009 -7.6% $101.82 24,314 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +9,450 +39% $0.000000 33,764 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $488,634 -4,799 -14% $101.82 28,965 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +14,845 +51% $0.000000 43,810 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $767,621 -7,539 -17% $101.82 36,271 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +28,779 +79% $0.000000 65,050 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $1,487,997 -14,614 -22% $101.82 50,436 23 Dec 2025 Direct F2
transaction EXAS Common Stock Options Exercise $0 +16,051 +32% $0.000000 66,487 23 Dec 2025 Direct F1
transaction EXAS Common Stock Tax liability $829,935 -8,151 -12% $101.82 58,336 23 Dec 2025 Direct F2
transaction EXAS Common Stock Award $0 +42,523 +73% $0.000000 100,859 23 Dec 2025 Direct F3
transaction EXAS Common Stock Tax liability $2,198,701 -21,594 -21% $101.82 79,265 23 Dec 2025 Direct F4
transaction EXAS Common Stock Award $0 +20,584 +26% $0.000000 99,849 23 Dec 2025 Direct F5
transaction EXAS Common Stock Tax liability $1,064,324 -10,453 -10% $101.82 89,396 23 Dec 2025 Direct F4
transaction EXAS Common Stock Award $0 +29,416 +33% $0.000000 118,812 24 Dec 2025 Direct F6
transaction EXAS Common Stock Tax liability $1,517,551 -14,938 -13% $101.59 103,874 24 Dec 2025 Direct F4
holding EXAS Common Stock 670 23 Dec 2025 Held in 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXAS Restricted Stock Units Options Exercise $0 -3,955 -100% $0.000000 0 23 Dec 2025 Common Stock 3,955 Direct F7, F8
transaction EXAS Restricted Stock Units Options Exercise $0 -9,450 -100% $0.000000 0 23 Dec 2025 Common Stock 9,450 Direct F7, F9
transaction EXAS Restricted Stock Units Options Exercise $0 -14,845 -100% $0.000000 0 23 Dec 2025 Common Stock 14,845 Direct F7, F10
transaction EXAS Restricted Stock Units Options Exercise $0 -28,779 -100% $0.000000 0 23 Dec 2025 Common Stock 28,779 Direct F7, F11
transaction EXAS Restricted Stock Units Options Exercise $0 -16,051 -100% $0.000000 0 23 Dec 2025 Common Stock 16,051 Direct F8, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units.
F3 Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation").
F4 Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units.
F5 Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F6 Represents performance-based restricted share units granted to the reporting person on February 24, 2025 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2027. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F7 Each restricted stock unit represents a contingent right to receive one share of common stock.
F8 This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F9 This award was scheduled to vest in two equal installments on February 27, 2026 and February 26, 2027, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F10 This award was scheduled to vest in three equal installments on February 27, 2026, February 26, 2027, and February 29, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F11 This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.
F12 This award was scheduled to vest in three equal installments on August 5, 2026, August 5, 2027, and August 5, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.